BLCO

Bausch + Lomb Corporation

$21.37

1.96%
SectorHealthcareIndustryMedical Instruments & SuppliesCountryCanada

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases.

Source: Yahoo Finance
AI summary

Price & performance

1M+19.0%
3M+25.9%
YTD+23.0%
1Y+31.9%
52-week range—
Beta1.12
Full chart and returns against a benchmark

Q-Score

59/ 100

Quality against peers; 50 is the peer median.

Growth59
Risk67
Performance49
Valuation69
Profitability56
Leverage41
Sentiment53
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$5.1B+6.5%
Net income-$360M
Net margin-7.1%-0.4 pts
Historical fundamentals

Revenue exposure

50%of revenue from outside the US
United Statesand Puerto Rico50%
Other Countries15%
China7%
Largest customer10%
Regions, segments, customers and suppliers

Valuation

BLCOIndustryP/E—49.36P/S1.413.73EV/EBITDA15.4323.12P/B1.193.92PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Oct 28next report, before the open
EPS estimate$0.22
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate